A New Frontier in HIV Prevention:
The
Role of Antiretroviral Drugs
A Plenary Talk and Symposium on Complex Issues Related to the Use of Antiretroviral (ARV) Medications for HIV Prevention
Co-sponsored by
the Global Community Core and the Ethics and Policy Core of the HIV Center and ICAP, Columbia University Mailman School of Public Health
Thursday, April 28, 2011
Moderators: Robert H. Remien, PhD and Robert Klitzman, MD
PLENARY TALK
PrEP: A Pill A Day to Keep HIV Away
Robert Grant, MD
Gladstone Institute of Immunology and Virology, UCSF
SYMPOSIUM
SESSION 1: PERSPECTIVES ON ARVS FOR PREVENTION
Kevin DeCock, MD
Center for Global Health, CDC
“What If There Is No HIV Vaccine?”
Slides
Wafaa El-Sadr, MD, MPH
ICAP, Columbia University
“HIV Treatment Is HIV Prevention: Case Closed?”
Robert Grant, MD
Gladstone Institute of Immunology and Virology, UCSF
“Thoughts for Optimal PREP Implementation”
SESSION 2: MAKING IT HAPPEN – IMPLICATIONS FOR IMPLEMENTATION
Steven Morin, PhD
CAPS and the AIDS Policy Research Center, UCSF
“When Combination HIV Prevention Works – How Much is Biomedical and
How Much Is Behavioral?”
Blayne Cutler, MD, PhD
Bureau of HIV/AIDS Prevention and Control, NYCDOHMH
“HIV in New York City: Bringing Science to the Street”
Bernard Lo, MD
Center for AIDS Prevention Studies, USCF
“Ethical and Policy Implications of Use of ARVs in Prevention”
Slides
"Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men"
New England Journal of Medicine
The Lancet
"Use of HIV Medications Reduces Risk of HIV Infection in Uninfected People"
Press Release from UCSF
iPrEx Study FAQ and fact sheets
iPrEx study materials from the National Institutes of Health (NIH):
Release
Additional information on PrEP from Global Advocacy for AIDS Prevention (AVAC)
Information on the iPrEx study drug, FTC/TDF
